As a market leading designer and manufacturer of disposable neurodiagnostic devices and consumables, Rhythmlink has experienced significant growth since its founding in 2002, and this investment from Graham will ensure that growth continues along with the innovation and quality that Rhythmlink is known for. The investment was completed on March 15, 2023.
“We’re excited about this next phase of Rhythmlink,” said Shawn Regan, CEO and Co-Founder. “Graham is an excellent partner for us because of their experience in medical technology and healthcare, and we see this as a growth opportunity for us to continue to innovate beyond our current capabilities,” said Regan. “I’m extremely proud of how far we’ve come, and this is a chance for Rhythmlink to expand our business without sacrificing what matters to us – improving patient care in our field of neurodiagnostics.”
This new relationship with Graham follows Rhythmlink’s extremely successful partnership with New Heritage Capital, a Boston-based private equity firm that invested in Rhythmlink in 2019. Under partnership with New Heritage Rhythmlink grew rapidly, acquired Chalgren Enterprises and expanded their existing product line to include EMG and NCV diagnostic consumable devices. Joe Straczek, COO and CFO for Rhythmlink, spoke on the success of this relationship.
“Our partnership with New Heritage was extremely beneficial,” said Straczek. “With their support, both financially and strategically, we were able to realize significant growth, particularly with the acquisition of Chalgren. We are immensely grateful for their partnership and guidance over the last four years.”
Rhythmlink sells a full line of consumable neurodiagnostic devices for Critical Care, electroencephalography, intraoperative neuromonitoring, the ER and ICU, and long-term epilepsy monitoring. More information about their products can be found online at www.Rhythmlink.com.